Epigenetic changes in patients with multiple sclerosis

Epigenetic changes influence gene expression without altering the DNA sequence. DNA methylation, histone modification and microRNA-associated post-transcriptional gene silencing are three key epigenetic mechanisms. Multiple sclerosis (MS) is a disease of the CNS with both inflammatory and neurodegenerative features. Although studies on epigenetic changes in MS only began in the past decade, a growing body of literature suggests that epigenetic changes may be involved in the development of MS, possibly by mediating the effects of environmental risk factors, such as smoking, vitamin D deficiency and Epstein–Barr virus infection. Such studies are also beginning to deliver important insights into the pathophysiology of MS. For example, inflammation and demyelination in relapsing–remitting MS may be related to the increased differentiation of T cells toward a T-helper 17 phenotype, which is an important epigenetically regulated pathophysiological mechanism. In progressive MS, other epigenetically regulated mechanisms, such as increased histone acetylation and citrullination of myelin basic protein, might exacerbate the disease course. In this Review, we summarize current knowledge on the role of epigenetic changes in the pathophysiology of MS.

[1]  Multiple sclerosis in 54 twinships: Concordance rate is independent of zygosity , 1992 .

[2]  Weiliang Qiu,et al.  Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. , 2012, Human molecular genetics.

[3]  A. Lutterotti,et al.  Smoking is a risk factor for early conversion to clinically definite multiple sclerosis , 2008, Multiple sclerosis.

[4]  G. Giovannoni,et al.  An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis , 2010, PloS one.

[5]  L. Blizzard,et al.  Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  N. Banik,et al.  Sodium Phenylacetate Inhibits Adoptive Transfer of Experimental Allergic Encephalomyelitis in SJL/J Mice at Multiple Steps1 , 2003, The Journal of Immunology.

[7]  D. Halbert,et al.  T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. , 2002, Cellular immunology.

[8]  P. Johnson,et al.  Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Gilles Edan,et al.  Evidence for a two-stage disability progression in multiple sclerosis , 2010, Brain : a journal of neurology.

[10]  J. A. Lozano,et al.  Differential Micro RNA Expression in PBMC from Multiple Sclerosis Patients , 2009, PloS one.

[11]  T. Dwyer,et al.  Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis , 2009, Journal of Neurology.

[12]  I. Adcock,et al.  Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  G. Teng,et al.  Shhh! Silencing by microRNA-155 , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[14]  I. Koturbash,et al.  Role of epigenetic events in chemical carcinogenesis—a justification for incorporating epigenetic evaluations in cancer risk assessment , 2011, Toxicology mechanisms and methods.

[15]  Jiuhong Kang,et al.  MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis , 2009, Nature Immunology.

[16]  C. Dinarello,et al.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. , 2008, The Journal of clinical investigation.

[17]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part I: The role of infection , 2007, Annals of neurology.

[18]  D Spiegelman,et al.  Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. , 2001, JAMA.

[19]  N. Rajewsky,et al.  Regulation of the Germinal Center Response by MicroRNA-155 , 2007, Science.

[20]  A. Chiarugi,et al.  The Therapeutic Potential of HDAC Inhibitors in the Treatment of Multiple Sclerosis , 2011, Molecular medicine.

[21]  Hristian,et al.  RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .

[22]  Thomas Tuschl,et al.  MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. , 2008, Immunity.

[23]  Sneha S. Joshi,et al.  1,25-Dihydroxyvitamin D3 Ameliorates Th17 Autoimmunity via Transcriptional Modulation of Interleukin-17A , 2011, Molecular and Cellular Biology.

[24]  A. Dueñas-González,et al.  Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial , 2010, Annals of Hematology.

[25]  H. Weiner,et al.  Silencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis , 2011, The Journal of Immunology.

[26]  G. Stephanopoulos,et al.  Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis , 2005, Journal of Neuroimmunology.

[27]  M. Moscarello,et al.  Deimination of Human Myelin Basic Protein by a Peptidylarginine Deiminase from Bovine Brain , 1993, Journal of neurochemistry.

[28]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[29]  L. Steinman A rush to judgment on Th17 , 2008, The Journal of experimental medicine.

[30]  A. Sadovnick,et al.  Parent-of-origin effects at the major histocompatibility complex in multiple sclerosis. , 2010, Human molecular genetics.

[31]  P. Rieckmann,et al.  The natural history of primary progressive multiple sclerosis , 2009, Neurology.

[32]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[33]  T. Bestor,et al.  Eukaryotic cytosine methyltransferases. , 2005, Annual review of biochemistry.

[34]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors , 2007, Annals of neurology.

[35]  D. Clayton,et al.  Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. , 1996, Brain : a journal of neurology.

[36]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[37]  K. Kyvik,et al.  Concordance for multiple sclerosis in Danish twins: an update of a nationwide study , 2005, Multiple sclerosis.

[38]  P. Adeleine,et al.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.

[39]  Tsung-Cheng Chang,et al.  microRNAs in vertebrate physiology and human disease. , 2007, Annual review of genomics and human genetics.

[40]  T. Gant,et al.  Smoking induces differential miRNA expression in human spermatozoa: A potential transgenerational epigenetic concern? , 2012, Epigenetics.

[41]  T. Kuhlmann,et al.  Changed Histone Acetylation Patterns in Normal-Appearing White Matter and Early Multiple Sclerosis Lesions , 2011, The Journal of Neuroscience.

[42]  Mathew B. Cox,et al.  MicroRNAs miR-17 and miR-20a Inhibit T Cell Activation Genes and Are Under-Expressed in MS Whole Blood , 2010, PloS one.

[43]  J. Minárovits,et al.  Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. , 2009, Seminars in cancer biology.

[44]  Michael K. Skinner,et al.  Epigenetic transgenerational actions of environmental factors in disease etiology , 2010, Trends in Endocrinology & Metabolism.

[45]  J. Mendell,et al.  MicroRNAs in cell proliferation, cell death, and tumorigenesis. , 2007, British journal of cancer.

[46]  T. Dwyer,et al.  Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis , 2010, Annals of neurology.

[47]  Caty Casas,et al.  Valproate reduces CHOP levels and preserves oligodendrocytes and axons after spinal cord injury , 2011, Neuroscience.

[48]  L. Martin,et al.  Epigenetic Regulation of Motor Neuron Cell Death through DNA Methylation , 2011, The Journal of Neuroscience.

[49]  A. Ballestrero,et al.  Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity , 2007, Clinical Cancer Research.

[50]  M. Fabbri,et al.  Regulatory mechanisms of microRNAs involvement in cancer , 2007, Expert opinion on biological therapy.

[51]  S. Muller,et al.  Epigenetic Histone Code and Autoimmunity , 2010, Clinical reviews in allergy & immunology.

[52]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[53]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[54]  A. Sadovnick,et al.  Multiple sclerosis: updated risks for relatives. , 1988, American journal of medical genetics.

[55]  Yu-Sun Chang,et al.  The Epstein–Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  C. Woodman,et al.  Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study , 2011, British Journal of Cancer.

[57]  M. Campbell,et al.  KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. , 2011, Human molecular genetics.

[58]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[59]  P. Casaccia‐Bonnefil,et al.  Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain , 2005, The Journal of cell biology.

[60]  J. Salzer Environmental risk factors for multiple sclerosis , 2013 .

[61]  D. Paty,et al.  A population-based study of multiple sclerosis in twins. , 1986, The New England journal of medicine.

[62]  Michael Weber,et al.  Genomic patterns of DNA methylation: targets and function of an epigenetic mark. , 2007, Current opinion in cell biology.

[63]  Qilong Yi,et al.  Methylation patterns of cell-free plasma DNA in relapsing–remitting multiple sclerosis , 2010, Journal of the Neurological Sciences.

[64]  L. Steinman,et al.  Impaired neurosteroid synthesis in multiple sclerosis. , 2011, Brain : a journal of neurology.

[65]  S. Di Giovanni,et al.  Multiple sclerosis in twins from continental Italy and Sardinia: A nationwide study , 2006, Annals of neurology.

[66]  A. Noor,et al.  Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated , 2007, Journal of neuroscience research.

[67]  J. Kaprio,et al.  Concordance and heritability of multiple sclerosis in Finland: study on a nationwide series of twins , 2008, European journal of neurology.

[68]  A. Sadovnick,et al.  Risks of multiple sclerosis in relatives of patients in Flanders, Belgium. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[69]  P. Janson,et al.  Profiling of CD4+ T Cells with Epigenetic Immune Lineage Analysis , 2011, The Journal of Immunology.

[70]  F. Mastronardi,et al.  The Role of Citrullinated Proteins Suggests a Novel Mechanism in the Pathogenesis of Multiple Sclerosis , 2006, Neurochemical Research.

[71]  J. Pers,et al.  Epigenetics and autoimmunity. , 2010, Journal of autoimmunity.

[72]  S. Gray,et al.  Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis , 2006, Epigenetics.

[73]  A. Kessels,et al.  Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis , 2008, Multiple sclerosis.

[74]  Eman N. Ali,et al.  Smoking and disease progression in multiple sclerosis. , 2009, Archives of neurology.

[75]  A. Bird,et al.  Genomic DNA methylation: the mark and its mediators. , 2006, Trends in biochemical sciences.

[76]  H. Lassmann,et al.  MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. , 2009, Brain : a journal of neurology.

[77]  M. Hernán,et al.  Cigarette smoking and incidence of multiple sclerosis. , 2001, American journal of epidemiology.

[78]  Emily Bernstein,et al.  RNA meets chromatin. , 2005, Genes & development.

[79]  George C. Ebers,et al.  The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.

[80]  Ryan M. O’Connell,et al.  MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. , 2010, Immunity.

[81]  Stephen L. Hauser,et al.  Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis , 2010, Nature.

[82]  C. Ackerley,et al.  Myelin in multiple sclerosis is developmentally immature. , 1994, The Journal of clinical investigation.

[83]  Ying Liang,et al.  Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. , 2006, Cancer research.

[84]  George A. Calin,et al.  Mammalian microRNAs: a small world for fine-tuning gene expression , 2006, Mammalian Genome.

[85]  M. Campbell,et al.  Vitamin D has wide regulatory effects on histone demethylase genes , 2012, Cell cycle.

[86]  M. Hernán,et al.  Cigarette smoking and the progression of multiple sclerosis. , 2005, Brain : a journal of neurology.